However, in contrast to previous “all comer”trials, these studies will recruit a genetically more homogenous group ofexclusively iCCA patients, and will help to determine the prognostic and predictivevalue of FGFR2 fusions in biliary tract cancer. This evidence concerns the gene FGFR2 and biliary tract neoplasm.